US 12,357,624 B2
Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
Michael Hayden, Herzliya (IL); Michal Geva, Even-Yehuda (IL); and Angela Cenci Nilsson, Lund (SE)
Assigned to Prilenia Neurotherapeutics Ltd., Yakum (IL)
Appl. No. 17/425,951
Filed by PRILENIA NEUROTHERAPEUTICS LTD., Herzliya (IL)
PCT Filed Feb. 4, 2020, PCT No. PCT/IL2020/050134
§ 371(c)(1), (2) Date Jul. 27, 2021,
PCT Pub. No. WO2020/161707, PCT Pub. Date Aug. 13, 2020.
Claims priority of provisional application 62/800,803, filed on Feb. 4, 2019.
Prior Publication US 2022/0193059 A1, Jun. 23, 2022
Int. Cl. A61K 31/451 (2006.01); A61P 25/16 (2006.01)
CPC A61K 31/451 (2013.01) [A61P 25/16 (2018.01)] 21 Claims
 
1. A method for treating, or slowing the progression of Parkinson's Disease in a subject wherein the Parkinson's Disease is associated with a glucocerebrosidase mutation (PD-GBA) wherein the method comprises administering a pharmaceutical composition comprising pridopidine or pharmaceutically acceptable salt thereof to the subject, wherein the pridopidine or pharmaceutically acceptable salt thereof is administered in a dosage of between 1 to 100 mg per day.